Silvio Danese outlines the 52-week TRUE NORTH study findings showing the benefits of ozanimod in patients with moderate-to-severe ulcerative colitis (4:11).
Silvio Danese outlines the 52-week TRUE NORTH study findings showing the benefits of ozanimod in patients with moderate-to-severe ulcerative colitis (4:11).
Don’t fall behind!
Get the latest headlines – in your specialties of choice – delivered straight to your inbox.
medwireNews Bureau Chief
